Human Breast Cancer Tissue Lysates
Pricing |
Normal Lysates: $125/100 ug |
Tumor Lysates: $175/100 ug |
Nor./Tum. set: $270.00 (10% off) |
Discounts |
2-8 Vials 10% |
9-20 Vials 15% |
>20 Vials 20% |
Introduction:
The following is a list of breast cancer histologic classifications. Infiltrating or invasive ductal cancer is the most common breast cancer histologic type and comprises 70% to 80% of all cases.
Carcinoma, NOS (not otherwise specified).
Ductal - Intraductal (in situ), Invasive with predominant Intraductal component, Invasive, NOS, Comedo (Inflammatory, Medullary with lymphocytic infiltrate, Mucinous (colloid), Papillary, Scirrhous, Tubular, Other).
Lobular - In situ, Invasive with predominant in situ component, Invasive.
Nipple - Paget�s disease, Paget�s disease with intraductal carcinoma, Paget�s disease with invasive ductal carcinoma.
Other - Undifferentiated carcinoma.
The following are tumor subtypes that occur in the breast but are not considered to be typical breast cancers - Cystosarcoma phyllodes, Angiosarcoma, Primary lymphoma.
Human Breast Cancer Tissue Lysates | ||||||
Catalog Number |
Diagnosis |
Grade |
Stage |
TNM |
Sex |
Age |
Ductal Carcinoma |
2 |
IIA |
T2N0M0 |
F |
54 |
|
Ductal Carcinoma |
2 |
IIIB |
T2N1M0 |
F |
36 |
|
Ductal Carcinoma |
2 |
IV |
T4N2Mx |
F |
61 |
|
Ductal Carcinoma |
2 |
II |
T2N0Mx |
F |
72 |
|
Ductal Carcinoma |
2 |
IV |
T4N2Mx |
F |
45 |
|
Ductal Carcinoma |
2 |
IIA |
T2N0M0 |
F |
42 |
|
Ductal Carcinoma |
2 |
IIB |
T2N1M0 |
F |
44 |
|
Ductal Carcinoma |
2 |
IIB |
T2N1M0 |
F |
39 |
|
Ductal Carcinoma |
2 |
IIIB |
T4bN1M0 |
F |
54 |
|
Ductal Carcinoma |
2 |
IIB |
T2N1M0 |
F |
54 |
|
Ductal Carcinoma |
2 |
IIB |
T3N0M0 |
F |
46 |
|
Ductal Carcinoma |
2 |
IIIB |
T4bN2M0 |
F |
55 |
|
Ductal Carcinoma |
2 |
IIB |
T2N1M0 |
F |
44 |
|
Ductal Carcinoma |
2 |
IIB |
T2N1M0 |
F |
63 |
|
Ductal Carcinoma |
2 |
IIB |
T2N1M0 |
F |
61 |
|
Ductal Carcinoma |
2 |
IIA |
T1N1M0 |
F |
61 |
|
Ductal Carcinoma |
2 |
IV |
T4N1Mx |
F |
85 |
|
Ductal Carcinoma |
2 |
IV |
T4N0M0 |
F |
75 |
|
Ductal Carcinoma |
2 |
II |
T2NxMx |
F |
47 |
|
Ductal Carcinoma |
3 |
IIA |
T2N0M0 |
F |
43 |
|
Ductal Carcinoma |
3 |
IIB |
T2N1M0 |
F |
61 |
|
Ductal Carcinoma |
3 |
IIB |
T2N1M0 |
F |
39 |
|
Ductal Carcinoma |
3 |
II |
T2N1Mx |
F |
35 |
|
Ductal Carcinoma |
3 |
III |
T3N1bMx |
F |
73 |
|
Ductal Carcinoma |
3 |
IIB |
T2N1M0 |
F |
50 |
|
Ductal Carcinoma |
3 |
IIIA |
T3N1M0 |
F |
52 |
|
Ductal Carcinoma |
3 |
IIIA |
T3N1M0 |
F |
49 |
|
Ductal Carcinoma |
3 |
II |
T2NxM0 |
F |
41 |
|
Ductal Carcinoma |
3 |
IV |
T4N1M0 |
F |
47 |
|
Ductal Carcinoma |
3 |
II |
T2N1M0 |
F |
55 |
|
Ductal Carcinoma |
3 |
II |
T2N0M0 |
F |
75 |
|
Ductal Carcinoma |
3 |
II |
T2N1M0 |
F |
53 |
|
Ductal Carcinoma |
3 |
II |
T2N1M0 |
F |
60 |
|
Ductal Carcinoma |
3 |
IV |
T4N2Mx |
F |
54 |
|
Ductal Carcinoma |
3 |
II |
T2N1M0 |
F |
43 |
|
Ductal Carcinoma |
3 |
II |
T2N1Mx |
F |
53 |
|
Ductal Carcinoma |
3 |
III |
T3N2M0 |
F |
43 |
|
Ductal Carcinoma |
3 |
II |
T2N1M0 |
F |
58 |
|
Mucinous Carcinoma |
1 |
II |
T2N1Mx |
F |
51 |
|
Ductal Carcinoma |
2 |
IIIB |
T4bN2M0 |
F |
48 |
|
Ductal Carcinoma |
2 |
IIIA |
T3N2M0 |
F |
42 |
|
Ductal Carcinoma |
2 |
II |
T2NxM0 |
F |
37 |
|
Ductal Carcinoma |
1 |
IIB |
T2N1M0 |
F |
51 |
|
Ductal Carcinoma |
1 |
IIIA |
T3N1M0 |
F |
47 |
|
Ductal Carcinoma |
1 |
IIIA |
T3N1M0 |
F |
38 |
|
Ductal Carcinoma |
1 |
IIA |
T2N0M0 |
F |
60 |
|
Ductal Carcinoma |
2 |
IIB |
T2N1M0 |
F |
32 |
|
Ductal Carcinoma |
1 |
IIB |
T2N1M0 |
F |
39 |
|
Mucinous Carcinoma |
2 |
IIIA |
T3N1M0 |
F |
43 |
|
Lobular Carcinoma |
n/a |
III |
T3N2M0 |
F |
39 |
|
Ductal Carcinoma |
3 |
III |
T3N2M0 |
F |
44 |
|
Mucinous Carcinoma |
n/a |
IB |
T2N0Mx |
F |
59 |
|
Metaplastic Carcinoma |
3 |
IV |
T4N1bMx |
F |
46 |
|
Intraductal Carcinoma |
2 |
IIA |
T2N0M0 |
F |
41 |
|
Intraductal Carcinoma |
2 |
IIB |
T2N1M0 |
F |
40 |
|
Intraductal Carcinoma |
2 |
IIA |
T2N0M0 |
F |
50 |
References:
Breast. In: American Joint Committee on Cancer.: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002., pp 171-180.
Yeatman TJ, Cantor AB, Smith TJ, et al.: Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222 (4): 549-59; discussion 559-61, 1995.
Chaney AW, Pollack A, McNeese MD, et al.: Primary treatment of Cystosarcoma phyllodes of the breast. Cancer 89 (7): 1502-11, 2000.